Cherwell Opens Expanded Redipor Prepared Media Manufacturing Facility
Cherwell Laboratories, manufacturer of Redipor prepared microbiological media, has completed an expansion programme at its Bicester-based facility. Initiated in response to a significant increase in demand, Cherwell has doubled the size of its cleanroom manufacturing suite and recruited additional staff to support the higher production capacity. Cherwell is renowned for offering a flexible supply of quality prepared media products, and the expanded facility ensures increasing demand in the UK and mainland Europe can be accommodated.
Cherwell’s continuing growth is partly fuelled by the development of export sales — up 55% in the past 2 years — and the appointment of further European distributors for the Redipor range. Already supported in Italy, Ireland, Poland and Slovenia, Cherwell has recently signed distributor agreements with AcefeSA in Spain and Dorte Egelund in Denmark. The company has carefully selected partners with the capability to deliver the same quality of service enjoyed by its UK customers.
The company has increased its UK market share through a dedication to customer service and the ability to deliver bespoke prepared media solutions. Many customers are switching to the convenience of Redipor pre-prepared media rather than making their own onsite. Increased pressure by regulators for more environmental monitoring has also led to overall growth in the prepared media market. Notably, demand for Redipor Barrier pack products, for use in isolators where vaporised hydrogen peroxide (VHP) is present, has grown, reflecting the increased use of VHP technology for sterilisation procedures.
Andy Whittard, Managing Director, Cherwell Laboratories commented: “This investment in facilities and capabilities is a clear indication of our commitment to developing our position as a leading supplier of prepared media. Recent market research shows our customers value not just the quality of our products, but increasingly our service and support. Most importantly, we are consistently delivering what our customers want.”
He added: “By developing our export markets through carefully selected partners, we aim to continue growing our UK-based production in a controlled manner, keeping excellent service and the customer at the core of what we do.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...